Clinical Efficacy and Safety of Biological Agents for the Treatment of Severe Acne Inversa
10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2021.0113
- VernacularTitle:生物制剂治疗中重度反常性痤疮的临床疗效及安全性评价
- Author:
Nai-yu LIN
1
;
Xu-hua TANG
1
;
Jian YANG
1
;
Zi-wei ZHOU
1
;
Jian-de HAN
1
;
1
Author Information
1. Department of Dermatology， The First Affiliated Hospital， Sun Yat-sen University， Guangzhou 510080， China
- Publication Type:Journal Article
- Keywords:
acne inversa;
hidradenitis suppurativa;
biological agent therapy;
Adalimumab;
Secukinumab
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2021;42(3):425-431
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo summarize the clinical efficacy and safety of biological therapy in treating acne inversa. MethodsTen patients diagnosed as acne inversa from January 2018 to December 2020 were recruited in the study. Hidradenitis suppurativa clinical response （HiSCR） and international hidradenitis suppurativa severity score system （ISH4） were used to evaluate the efficacy of adalimumab therapy and/or secukinumab therapy. ResultsNine patients were treated with adalimumab and 3 patients were treated with secukinumab. Among patients with adalimumab， the ISH4 decline rate was 45.5%（26.2%～94.7%）and 5 of them reached HiSCR. Among patients with secukinumab， two of them were transfered from the adalimumab therapy， the ISH4 decline rate of each patient was 5%，34.3% and 70.8%，and 1 of them reached HiSCR. There were no severe side effects， such as serious infection and malignant tumor， seen in all the patients. Two patients were switched from adalimumab to secukinumab due to treatment resistance and potential risk of infection. The remaining patients had no clinical side effects， such as tuberculosis， hepatitis， elevated liver enzymes， and urticaria， during the treatment period. ConclusionsBiological agents are quite effective in treating acne inversa， which provides a new option for these patients. However， it is still necessary to conduct a comprehensive evaluation of patients before initiating this therapy.
